The high incidence and prevalence of tuberculosis (TB) are a continuous global public health problem of enormous proportions. AIDS and the development of multidrug-resistant Mycobacterium tuberculosis have aggravated this problem. Our understanding of the components of protective M. tuberculosis immunity specifically in the human host is still fragmented and contradictory. A better understanding of protective human immune responses, however, is needed for the development of new antituberculous treatment and vaccination approaches for use against infection with M. tuberculosis and human TB (13, 14, 44) . The role of innate immune mechanisms in the protective immune response against M. tuberculosis is particularly poorly understood (43) . Epidemiological data provide evidence that human protective immunity against M. tuberculosis exists (14) . Individuals who are exposed to infectious patients with TB but remain tuberculin skin test negative and do not show evidence of adaptive immune responses may be models of innate protective immune mechanisms. While systemic immunity appears to play a dominant role in preventing dissemination of M. tuberculosis, local pulmonary host defenses probably determine the outcome of the primary infection.
In the murine model, acquired T-cell immunity protects against disseminated disease but does not prevent initial aerogenic pulmonary infection (7, 33) . In humans, natural acquired M. tuberculosis-specific T-cell immunity similarly does not prevent exogenous reinfection in the lung (44) .
We previously demonstrated compartmentalization of activated alveolar lymphocytes and increased M. tuberculosis antigen-specific production of gamma interferon (IFN-␥) in the bronchoalveolar spaces of patients with active TB (37) . As bronchoalveolar cells (BAC) were obtained by bronchoalveolar lavage (BAL) from the sites of active TB disease, activation of alveolar lymphocytes and increased antigen-specific production of IFN-␥ alone appeared to be insufficient to control M. tuberculosis replication and disease. Recent studies with bacillus Calmette-Guérin (Mycobacterium bovis BCG)-vaccinated subjects also showed that IFN-␥ production did not correlate with protection as determined by functional in vitro killing assays (8) . Additional immune mechanisms that confer protection in the lung and additional correlates of protection thus remain to be defined. Because it is conceivable that local Tcell-independent innate host immune mechanisms are involved in protection against primary pulmonary M. tuberculosis infection, we have begun to assess induction of human ␤-defensin 2 (HBD-2) in alveolar epithelial cell line A549 upon infection with M. tuberculosis.
HBD-2 is a cationic antimicrobial peptide that has a low molecular weight (4,000) (29) and exhibits a wide range of antimicrobial activity against viruses, bacteria, and fungi (9, 26, 29, 40a) . Defensins can be divided into the alpha, beta, and theta groups, depending on the position of cysteines and disulfide bridges (3, 25, 29) . Four different human ␤-defensin peptides have been described to date (9, 17, 19, 21) , although numerous homologous genes have been observed in the human genome (27, 34, 36) . While expression of HBD-1 is generally constitutive, levels of HBD-2 and HBD-3 mRNA can be induced by interleukin-1, tumor necrosis factor (TNF), bacteria, and fungi (26, 29, 40a) . HBD-2 gene expression has been identified in various human epithelia, such as epithelia from skin, lungs, trachea, and the urogenital system (2, 26, 29, 31, 39, 40a) . HBD-2 has also been detected in bronchoalveolar lavage fluid from patients with Mycobacterium avium-intracellulare infection (1). Kisich et al. demonstrated that HBD-2-transfected blood monocytes (MN) control M. tuberculosis growth better than native MN, suggesting that HBD-2 plays a role in immunity against M. tuberculosis (28).
Because of its chemotactic effects on immature dendritic cells and memory lymphocytes (46) , HBD-2 may constitute a link between innate and acquired immune responses.
M. tuberculosis is transmitted primarily by the respiratory route, and in the majority of cases human TB is a pulmonary disease (13, 43, 45 
MATERIALS AND METHODS
Study subjects. Seven healthy subjects (five men and two women; ages, 24 to 40 years) were recruited at the National Institute for Respiratory Diseases (INER) in Mexico City. All subjects had a normal chest X ray, and none had a upper respiratory tract infection; all had negative serology for human immunodeficiency virus. Following written informed consent, the study subjects underwent venipuncture and fiberoptic bronchoscopy with BAL. Consent to perform these studies was obtained from the study subjects by a Spanish-speaking study nurse and physician and was obtained according to the guidelines of the U.S. polystyrene dishes (Costar, Ontario, Canada) containing RPMI medium supplemented with 10% human AB serum (Gemini, Woodland, CA). After 2 h of incubation in the presence of 5% CO 2 at 37°C, nonadherent cells were removed by washing with warm RPMI medium. The remaining adherent cells (referred to as blood monocytes) were incubated at 4°C for 1 h with Hanks salt solution (BioWhittaker, Walkersville, MD) and then removed with a cell scraper, counted, and readhered in 24-well plates (Costar, Corning, N.Y.) at a concentration of 10 6 cells per well for 2 h prior to M. tuberculosis infection. Cytospin preparations were prepared from adherent uninfected cells to allow evaluation of the nuclear and cellular morphology by Wright's staining.
Alveolar macrophages. To obtain BAC, BAL was performed with seven healthy donors as previously described (38) . Briefly, 150 ml of a 0.9% sterile sodium chloride solution was instilled into each of two segments of the right lung. A total of 200 to 250 ml of the saline was retrieved from each subject. BAC were obtained by centrifugation (1,200 rpm, 15 min, 4°C) of the BAL fluid. AM were then enriched from the BAC by removal of alveolar lymphocytes with sheep red blood cell (SRBC) rosetting. To do this, 500 l of SRBC was mixed with 500 l of neuraminidase (Sigma Chemical Co., St. Louis, MO), incubated for 1 h at 37°C, washed with 1ϫ Hanks balance salt solution, and then resuspended in RPMI medium. Two milliliters of neuraminidase-treated SRBC and 2 ml of fetal calf serum were added to each preparation containing 1 ϫ 10 7 to 2 ϫ 10 7 BAC/ml, and the cell mixtures were incubated for 10 min at 37°C. SRBC-treated BAC were then centrifuged at 400 ϫ g for 10 min at 4°C. The pelleted cells were incubated for 1 h on ice and centrifuged over a Ficoll density gradient. Ninetyfive percent of the cells from the interface had morphological characteristics of AM as determined by Wright's staining of cytospins.
In vitro infection and cell stimulation. (i) AM and MN. AM and MN were plated separately in 24-well dishes at a concentration of 10
5 cells per well with RPMI 1640 containing gentamicin and L-glutamine and adhered for 2 h in the presence of 5% CO 2 at 37°C. The culture medium was then carefully removed, and cells were infected with M. tuberculosis in RPMI medium supplemented with 30% non-heat-inactivated pooled human AB serum. AM and MN were not treated (medium alone), were infected at multiplicities of infection (MOI) (bacterium/cell ratios) of 0.1:1, 1:1, 5:1, and 10:1 for M. tuberculosis and 200:1 for P. aeruginosa, or were stimulated with LPS (10 g/ml). Cells were then incubated at 37°C with 5% CO 2 for 1, 18, 24, and 48 h and lysed in 200 l TRIzol reagent (Gibco BRL, Grand Island, NY) per 10 6 cells, and the lysates were stored at Ϫ80°C.
(ii) Human alveolar epithelial cell line A549. A549 cells were plated in 24-well dishes at a concentration of 10 6 cells/well and were preincubated for 24 h prior to M. tuberculosis infection in DMEM with 2% fetal calf serum. A549 cells were infected separately with M. tuberculosis at MOI of 0.1:1, 1:1, 5:1, and 10:1 and with P. aeruginosa at an MOI of 200:1. Infection of A549 cells was confirmed using Ziehl-Neelsen stain. The following stimuli were used to induce HBD-2 expression and production: LPS (10 g/ml), rhTNF (1 ng/ml), and manLAM (10 g/ml). Following 1, 6, 12, 18, 24, and 48 h of incubation, A549 cells were lysed in TRIzol reagent, and the lysates were stored at Ϫ20°C.
RNA extraction. RNA was extracted from the cell lysates by adding 20 l of chloroform-isoamyl alcohol (49:1) and vortexing the mixture, followed by centrifugation at 14,000 rpm for 15 min at 4°C. The aqueous phase was then mixed with cold isopropanol, chilled on ice for 15 min, and centrifuged, and the RNA pellet was washed once with cold 75% ethanol. The pelleted RNA was then dried at 65°C and resuspended in 13 l of diethyl pyrocarbonate-treated water.
Reverse transcription and cDNA synthesis. HBD-2 mRNA was reverse transcribed using oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers (Invitrogen, Carlsbad, CA) and a commercial kit (Superscript II; Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Briefly, RNA was mixed with a reaction mixture that contained 10ϫ PCR buffer, 25 mM MgCl 2 , each deoxynucleoside triphosphate at a concentration of 10 mM, and the reverse transcriptase enzyme. The final mixture was synthesized in a thermocycler (iCycler; Bio-Rad, Hercules, CA). cDNA concentrations were then measured with a spectrophotometer at a ratio of UV absorbance at 260 nm to UV absorbance at 280 nm.
HBD-2 PCR. The primers used for a 102-bp HBD-2 gene fragment were 5Ј-CAT CAG CCA TGA GGG TCT-3Ј (forward) and 5Ј-AGG CAG GTA ACA GGA TCG-3Ј (reverse) (10). The primers used for a 110-bp fragment of glyc-eraldehyde 3-phosphate dehydrogenase (GAPDH) (constitutive gene expression control) were 5Ј-CAT CAC CAT CTT CCA GGA GC-3Ј (forward) and 5Ј-GGA TGA TGT TCT GGA GA-3Ј (reverse) (21) .
One microgram of cDNA was added to a reaction mixture containing PCR buffer, MgCl 2 (10 mM), deoxynucleoside triphosphates (25 mM), 1 U of Taq polymerase (Invitrogen, Carlsbad, CA), and the forward and reverse primers for HBD-2 or GAPDH (20 ng). The HBD-2 and GAPDH cDNA were amplified with the following settings: 30 s of denaturation at 95°C, 30 s of annealing at 56°C (HBD-2) or 63°C (GAPDH), and 1 min of extension at 72°C for 35 cycles and a 10-min extension step at 72°C after the last cycle. The resulting HBD-2 and GAPDH cDNA amplicons were kept at Ϫ20°C until visualization by electrophoresis on 3% agarose gels stained with ethidium bromide.
cDNA samples obtained from A549 cells that had been stimulated either with 500 pg of rhTNF or with the P. aeruginosa mucoid strain at an MOI of 200:1 were used to generate positive control bands for HBD-2 (20) . cDNA samples from AM, MN, and A549 cells that had been incubated in culture medium without stimuli were used as negative controls.
HBD-2 immunocytochemistry and fluorescent M. tuberculosis staining. A549 cells were grown to confluence (95%) on four-well chamber slides (Costar, Ontario, Canada). After M. tuberculosis infection, cells were fixed with formaldehyde (10%) for 24 h and stored at 4°C in phosphate-buffered saline (PBS). An immunocytochemistry analysis of HBD-2 and H37Rv was done as previously described (19) . Briefly, slides were blocked with 5% goat serum for 20 min and then incubated either with a 1:5,000 dilution of HBD-2 antibody or with preimmune serum (both gifts from Tomas Ganz) in 5% goat serum at 4°C for 18 h. The slides were then developed with biotinylated goat anti-rabbit immunoglobulin G (IgG) using a Vectastain ABC kit (Vector Laboratories, Burlingame, CA). Following the immunostaining of HBD-2, the slides were acid-fast stained with auramine-O to detect M. tuberculosis using the BBL TB fluorescent stain (Becton Dickinson, Franklin Lakes, NJ) as described by the manufacturer. HBD-2 and M. tuberculosis were then visualized by fluorescent microscopy.
Subcellular detection of HBD-2 by immunoelectron microscopy. A549 cells were infected with M. tuberculosis as described above. After 24 h, infected and uninfected (control) A549 cells were washed three times with PBS, fixed in 4% (vol/vol) paraformaldehyde, and dissolved in 0.2 M Sörensen buffer (1 volume of NaH2PO4 · H 2 O, 2 volumes of NaHPO4 · 7H 2 O) at pH 7.3 for 2 h at 4°C. Following washing of the cells with Sörensen buffer, free aldehyde groups were blocked with 0.5 M ammonium chloride in PBS for 1 h. Fixed cells were then dehydrated with a graded ethyl alcohol series and embedded in LR-White hydrosoluble resin (London Resin Co., Hampshire, United Kingdom). Thin sections that were 70 to 90 nm thick were placed on nickel grids. The grids were incubated overnight at 4°C with specific polyclonal rabbit anti-HBD-2 antibody (Peptide International, Osaka, Japan) diluted 1/200 in PBS with 1% bovine serum albumin and 0.5% Tween 20. After rinsing with PBS, the grids were incubated for 1 h at room temperature with goat anti-rabbit IgG (Sigma Chemical Co., St. Louis, MO) conjugated to 10-nm gold particles (Sigma) diluted 1/20 in PBS. The grids were stained with uranium salts (Electron Microscopy Sciences, Fort Washington, PA) and examined with an M-10 Zeiss electron microscope (Karl Zeiss, Jena Germany). For negative controls, the primary HBD-2 antibody was replaced by normal rabbit serum. (Fig. 2) . (Fig. 3) .
RESULTS

Expression of HBD-2 in
A summary of the HBD-2 expression results for the different kinds of cells and stimuli is shown in Table 1 .
Detection of HBD-2 by immunocytochemistry. Figure 4 shows HBD-2 within A549 cells following infection with M. tuberculosis. Slides were developed with biotinylated goat antirabbit IgG using a Vectastain ABC kit (Vector Laboratories, Burlingame, CA). In Fig. 5A , M. tuberculosis is visible due to auramine staining. Maximal HBD-2 expression was visible in the areas where M. tuberculosis was localized, and this suggests that there was an intracellular interaction between of HBD-2 and M. tuberculosis (Fig. 5B) .
Detection of HBD-2 by electron microscopy. Electron microscopy showed that specific immunolabeling of HBD-2 was localized in the mycobacterial cell wall and the cytoplasm of extracellular bacteria (Fig. 6B and C) , as well as in bacteria that were attached to the external surface of the cell membrane (Fig. 6B) . The same pattern of subcellular HBD-2 distribution was found in intracellular mycobacteria (Fig. 6C and D) .
Interestingly, specific HBD-2 immunolabeling was also seen in disrupted intracellular bacilli (Fig. 6D) . Noninfected control cells or M. tuberculosis-infected cells that were incubated without the primary anti-HBD-2 antibodies did not show immunolabeling for HBD-2 (not shown).
DISCUSSION
Innate immunity is the first line of defense against invading microorganisms in vertebrate organisms and triggers antigenspecific adaptive immune responses (43) . Antimicrobial peptides are thought to be effectors of innate immunity through their antibiotic activity and direct killing of microorganisms (3) HBD-2 is produced by epithelial cells in the respiratory tract and may be relevant in the pathogenesis of several diseases (1, 24, 40, 40a) . High salt concentrations in the lung fluids of cystic fibrosis patients, for example, are associated with the functional impairment of HBD-2 that is associated with increased susceptibility to respiratory bacterial infections, such P. aeruginosa infections (40). Harder and coworkers (20) showed that human type II pneumocytes of the A549 cell line induced the HBD-2 gene and allowed isolation of the peptide from culture supernatants following in vitro infection with mucoid P. aeruginosa.
Whether HBD-2 is involved in the innate immunity against intracellular pathogens such as M. tuberculosis has not been determined. This is the first peaks at 18 and 24 h postinfection. HBD-2 gene expression at a late time, 48 h, raised the question whether HBD-2 gene expression was due to direct M. tuberculosis infection alone and/or due to secondary events, such as interleukin-1␤ release from surrounding M. tuberculosis-infected or uninfected bystander cells as well.
Interestingly, LPS induction of HBD-2 was poor in A549 cells, whereas mucoid P. aeruginosa strongly induced HBD-2. The nonmucoid strain of P. aeruginosa resulted in only marginal HBD-2 induction (data not shown). This finding suggests that alginate, a prevalent antigen of a mucoid strain, may be an inducer of HBD-2.
As previously shown, TNF (20) induces the expression of HBD-2 in A549 cells. In the present study, TNF was used as a positive control for HBD-2 induction in A549 cells. Interestingly, TNF is produced by AM upon infection with M. tuberculosis (22, 33) and has a key role in the formation and maintenance of immune granulomas (22) . Because TNF is an inducer of HBD-2 expression in pulmonary epithelial cells, modulated by NFB (42), we hypothesize that in vivo expression of HBD-2 can be modulated both by a direct effect of M. tuberculosis on the alveolar epithelium and by TNF that is released from M. tuberculosis-infected AM.
We were interested in assessing if manLam could be a component of M. tuberculosis that induces the induction of HBD-2 in A549 cells. manLam is one of the most important lipid components of the cell wall of M. tuberculosis (6, 18) and plays an important role in the adherence and phagocytosis of M. tuberculosis in macrophages (35) . Our finding that there was HBD-2 gene expression following stimulation of A549 cells with manLAM suggests that manLAM may be one of the components of M. tuberculosis that is responsible for the induction of HBD-2 gene expression.
Previous reports demonstrated that induction of HBD-2 expression requires Toll-like receptor 2 (TLR2)-mediated intracellular signaling (5, 41) . Interestingly, A549 cells express TLR2, which activates NFB to induce production of HBD-2 (5). We therefore hypothesize that M. tuberculosis induction of HBD-2 may depend on the interaction of manLAM with TLR2.
In vitro studies suggest that HBD-2 is involved in M. tuberculosis growth control. Kisich et al. showed that transfection of human MN-derived macrophages with the HBD-2 gene (28) increased the capacity of HBD-2 transfected MN to control M. tuberculosis growth compared with non-HBD-2-transfected MN-derived macrophages.
M. tuberculosis has been shown to be capable of invading alveolar epithelial cells (4), and type II pneumocytes are among the first cells in the alveolar spaces to come in contact with M. tuberculosis during a primary aerogenic infection (4, 43) . In autopsy material from TB patients, M. tuberculosis DNA was found in type II pneumocytes, suggesting that these cells play a role in the pathogenesis of TB in vivo (23) . Type II pneumocytes produce chemokines (30) and collectins, such as SP-A and SP-B (32), molecules that are important in the control of microbial invasion and defense against M. tuberculosis. However, so far there is no direct evidence that defensins are produced in vivo by type II pneumocytes during M. tuberculosis infection Our PCR and immunocytochemistry data demonstrate that mycobacterial infection of A549 cells induces not only HBD-2 gene expression but also production of intracellular HBD-2. At the light microscopy level, the pattern of HBD-2 immunostaining suggests that HBD-2 production is induced by intracellular M. tuberculosis. This observation was corroborated by the immunoelectron microscopy findings that showed HBD-2 labeling in the mycobacterial cytoplasm and cell wall. Interestingly, extracellular bacilli that were in direct contact with the A549 cells also showed HBD-2 labeling, suggesting that not only intracellular bacteria but also extracellular bacilli can be targeted by HBD-2. HBD-2 labeling of intracellular disrupted M. tuberculosis bacilli may allow speculation concerning participation of HBD-2 in intracellular mycobacterial killing. Bactericidal effects of HBD-2 from A549 cells may contribute to M. tuberculosis control. However, HBD-2 has also been shown to elicit chemokine-like activities (12) . other authors failed to demonstrate HBD-2 production by MN (28) . We have shown that HBD-2 gene expression is induced by LPS in MN. However, this was the case in only two of seven of our study subjects, a finding that corroborates earlier observations that not all subjects express HBD-2 under the same conditions (16) . HBD-2 expression thus may depend on alterations of TLR4 expression or function or on genetic HBD-2 polymorphisms. We did not observe HBD-2 gene expression in M. tuberculosis-infected MN or MN-derived macrophages from the subjects studied (data not shown). However, due to the small number of subjects that were studied, induction of HBD-2 production by MN or macrophages by M. tuberculosis cannot be firmly excluded. Future studies may address in vivo HBD-2 expression in individuals with various levels of resistance to M. tuberculosis exposure.
In summary, our results show that A549 cells efficiently produce HBD-2 upon in vitro infection with M. tuberculosis and suggest that HBD-2 from lung epithelial cells may be a component of the innate immune response against M. tuberculosis both in the primary infection and in the immunopathogenesis of human TB.
